Dr. Reddy’s Laboratories Ltd. expects its generic anti-obesity drug to shore up growth in the six months through March after it resolves an impurity issue with the key ingredient and resumes supply in early November.
Dr. Reddy’s Laboratories Ltd. expects its generic anti-obesity drug to shore up growth in the six months through March after it resolves an impurity issue with the key ingredient and resumes supply in early November.
Lire l’article complet sur le site source
Bloomberg — Markets (EN)